Zobrazeno 1 - 10 of 165 pro vyhledávání: '"Scott F. Huntington"'
1
Akademický článek
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Autor: Nikolai A. Podoltsev, Rong Wang, Rory M. Shallis, Jessica M. Stempel, Mengyang Di, Natalia Neparidze, Amer M. Zeidan, Scott F. Huntington, Smith Giri, Sarah C. Hull, Steven D. Gore, Xiaomei Ma
Publikováno v: Cancer Medicine, Vol 12, Iss 18, Pp 18889-18900 (2023)
Abstract Background Polycythemia vera (PV) and essential thrombocythemia (ET) are linked to increased risk of cardiovascular morbidity and mortality. In addition to the reduction in of arterial thrombotic events, statins may prevent venous thrombosis
Externí odkaz: https://doaj.org/article/37b984a3a27e4915a681f12f7319c9f7
Zobrazit plný text záznamu
3
Akademický článek
Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Autor: Scott F. Huntington, Sreevalsa Appukkuttan, Wenyi Wang, Yuxian Du, Sari Hopson, Svetlana Babajanyan
Publikováno v: Journal of Health Economics and Outcomes Research, Vol 9, Iss 2 (2022)
**Background:** A consensus is lacking on optimal treatment sequencing for follicular lymphoma (FL), the most common indolent lymphoma. FL is incurable, and many patients require multiple lines of therapy for successive relapses. Guidelines provide n
Externí odkaz: https://doaj.org/article/0aaaf38c96e9474fae346c6e3cd9c96b
Zobrazit plný text záznamu
4
Akademický článek
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
Autor: Rory M. Shallis, Rong Wang, Jan P. Bewersdorf, Amer M. Zeidan, Amy J. Davidoff, Scott F. Huntington, Nikolai A. Podoltsev, Xiaomei Ma
Publikováno v: Therapeutic Advances in Hematology, Vol 12 (2021)
Introduction: The choice of BCR-ABL1 tyrosine kinase inhibitors (TKI) for the first line of therapy (LOT) for chronic-phase chronic myeloid leukemia (CML) is tailored to disease risk and patient characteristics like comorbidities, which become more p
Externí odkaz: https://doaj.org/article/f9cb5ac8d0f14aa8b6c4e76d443c97fb
Zobrazit plný text záznamu
5
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Autor: Jan Philipp Bewersdorf, Scott F. Huntington, Amer M. Zeidan
Publikováno v: Journal of the National Comprehensive Cancer Network. 21:522-528
Acute myeloid leukemia (AML) is the most common acute leukemia in adults in the United States and has seen the approval of several novel agents over the past decade. Similar to treatments for other hematologic and solid malignancies, these novel agen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14b1e0f4535842bd77652586d2caa484
https://doi.org/10.6004/jnccn.2023.70012
Zobrazit plný text záznamu
7
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
Autor: Kunal C. Potnis, Mengyang Di, Iris Isufi, Lohith Gowda, Stuart E. Seropian, Francine M. Foss, Howard P. Forman, Scott F. Huntington
Publikováno v: Blood Advances. 7:801-810
Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) FL after
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ffe3b900d8bace834ad4990a0d446b1
https://doi.org/10.1182/bloodadvances.2022008097
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje